These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 25494920)
1. Francisella tularensis LVS surface and membrane proteins as targets of effective post-exposure immunization for tularemia. Chandler JC; Sutherland MD; Harton MR; Molins CR; Anderson RV; Heaslip DG; Bosio CM; Belisle JT J Proteome Res; 2015 Feb; 14(2):664-75. PubMed ID: 25494920 [TBL] [Abstract][Full Text] [Related]
2. Francisella tularensis Live Vaccine Strain deficient in capB and overexpressing the fusion protein of IglA, IglB, and IglC from the bfr promoter induces improved protection against F. tularensis respiratory challenge. Jia Q; Bowen R; Lee BY; Dillon BJ; Masleša-Galić S; Horwitz MA Vaccine; 2016 Sep; 34(41):4969-4978. PubMed ID: 27577555 [TBL] [Abstract][Full Text] [Related]
3. Post-exposure immunization against Francisella tularensis membrane proteins augments protective efficacy of gentamicin in a mouse model of pneumonic tularemia. Sutherland MD; Goodyear AW; Troyer RM; Chandler JC; Dow SW; Belisle JT Vaccine; 2012 Jul; 30(33):4977-82. PubMed ID: 22652404 [TBL] [Abstract][Full Text] [Related]
4. Oral immunization of mice with the live vaccine strain (LVS) of Francisella tularensis protects mice against respiratory challenge with virulent type A F. tularensis. KuoLee R; Harris G; Conlan JW; Chen W Vaccine; 2007 May; 25(19):3781-91. PubMed ID: 17346863 [TBL] [Abstract][Full Text] [Related]
6. Identification of immunoreactive antigens in membrane proteins enriched fraction from Francisella tularensis LVS. Janovská S; Pávková I; Hubálek M; Lenco J; Macela A; Stulík J Immunol Lett; 2007 Feb; 108(2):151-9. PubMed ID: 17241671 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of the live attenuated Francisella tularensis vaccine (LVS) in a murine model of disease. Green M; Choules G; Rogers D; Titball RW Vaccine; 2005 Apr; 23(20):2680-6. PubMed ID: 15780452 [TBL] [Abstract][Full Text] [Related]
8. Construction and characterization of an attenuated purine auxotroph in a Francisella tularensis live vaccine strain. Pechous R; Celli J; Penoske R; Hayes SF; Frank DW; Zahrt TC Infect Immun; 2006 Aug; 74(8):4452-61. PubMed ID: 16861631 [TBL] [Abstract][Full Text] [Related]
9. Immunoproteomics analysis of the murine antibody response to vaccination with an improved Francisella tularensis live vaccine strain (LVS). Twine SM; Petit MD; Fulton KM; House RV; Conlan JW PLoS One; 2010 Apr; 5(4):e10000. PubMed ID: 20368994 [TBL] [Abstract][Full Text] [Related]
10. Preclinical testing of a vaccine candidate against tularemia. Suresh RV; Ma Z; Sunagar R; Bhatty V; Banik S; Catlett SV; Gosselin EJ; Malik M; Bakshi CS PLoS One; 2015; 10(4):e0124326. PubMed ID: 25897786 [TBL] [Abstract][Full Text] [Related]
11. Aerosol-, but not intradermal-immunization with the live vaccine strain of Francisella tularensis protects mice against subsequent aerosol challenge with a highly virulent type A strain of the pathogen by an alphabeta T cell- and interferon gamma- dependent mechanism. Wayne Conlan J; Shen H; Kuolee R; Zhao X; Chen W Vaccine; 2005 Mar; 23(19):2477-85. PubMed ID: 15752834 [TBL] [Abstract][Full Text] [Related]
12. Proteomic analysis of anti-Francisella tularensis LVS antibody response in murine model of tularemia. Havlasová J; Hernychová L; Brychta M; Hubálek M; Lenco J; Larsson P; Lundqvist M; Forsman M; Krocová Z; Stulík J; Macela A Proteomics; 2005 May; 5(8):2090-103. PubMed ID: 15892173 [TBL] [Abstract][Full Text] [Related]
13. A novel receptor - ligand pathway for entry of Francisella tularensis in monocyte-like THP-1 cells: interaction between surface nucleolin and bacterial elongation factor Tu. Barel M; Hovanessian AG; Meibom K; Briand JP; Dupuis M; Charbit A BMC Microbiol; 2008 Sep; 8():145. PubMed ID: 18789156 [TBL] [Abstract][Full Text] [Related]
14. Inactivated Francisella tularensis live vaccine strain protects against respiratory tularemia by intranasal vaccination in an immunoglobulin A-dependent fashion. Baron SD; Singh R; Metzger DW Infect Immun; 2007 May; 75(5):2152-62. PubMed ID: 17296747 [TBL] [Abstract][Full Text] [Related]
15. Proteome analysis of an attenuated Francisella tularensis dsbA mutant: identification of potential DsbA substrate proteins. Straskova A; Pavkova I; Link M; Forslund AL; Kuoppa K; Noppa L; Kroca M; Fucikova A; Klimentova J; Krocova Z; Forsberg A; Stulik J J Proteome Res; 2009 Nov; 8(11):5336-46. PubMed ID: 19799467 [TBL] [Abstract][Full Text] [Related]
16. Development of a Multivalent Subunit Vaccine against Tularemia Using Tobacco Mosaic Virus (TMV) Based Delivery System. Banik S; Mansour AA; Suresh RV; Wykoff-Clary S; Malik M; McCormick AA; Bakshi CS PLoS One; 2015; 10(6):e0130858. PubMed ID: 26098553 [TBL] [Abstract][Full Text] [Related]
17. Generation and characterization of hybridoma antibodies for immunotherapy of tularemia. Lu Z; Roche MI; Hui JH; Unal B; Felgner PL; Gulati S; Madico G; Sharon J Immunol Lett; 2007 Oct; 112(2):92-103. PubMed ID: 17764754 [TBL] [Abstract][Full Text] [Related]